Janssen chalks up two more indications in Europe for Imbruvica combo therapies

Janssen’s has secured a label expansion from the European Commission for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib), approving the therapy in two new indications.

The ruling authorises Imbruvica in combination with obinutuzumab for the treatment of chronic lymphocytic leukaemia (CLL), and in combination with rituximab for the treatment of Waldenström’s macroglobulinemia (WM), both in adult patients. The drug was jointly developed by Janssen and AbbVie’s Pharmacyclics.

read more